MA38949A1 - Forme saline d'hydrochlorure pour inhibition d'ezh2 - Google Patents

Forme saline d'hydrochlorure pour inhibition d'ezh2

Info

Publication number
MA38949A1
MA38949A1 MA38949A MA38949A MA38949A1 MA 38949 A1 MA38949 A1 MA 38949A1 MA 38949 A MA38949 A MA 38949A MA 38949 A MA38949 A MA 38949A MA 38949 A1 MA38949 A1 MA 38949A1
Authority
MA
Morocco
Prior art keywords
dgat1
ezh2
hydrochloride
inhibition
saline form
Prior art date
Application number
MA38949A
Other languages
English (en)
Inventor
Kevin W Kuntz
Hyeong-Wook Choi
Steven Mathieu
Kristen Sanders
Arani Chanda
Original Assignee
Eisai R&D Man Co Ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Epizyme Inc filed Critical Eisai R&D Man Co Ltd
Publication of MA38949A1 publication Critical patent/MA38949A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés qui sont des inhibiteurs d'acyl-coenzyme a: diacylglycérol transférase 1 (dgat1), des compositions pharmaceutiques les contenant, des procédés pour leur préparation, ainsi que leur utilisation en thérapie, seuls ou en combinaison avec des thérapies de gestion du poids ou autre thérapie de diminution des triglycérides pour la prévention ou le traitement de maladies liées à un dysfonctionnement de dgat1 ou dans lesquelles une modulation de l'activité de dgat1 peut avoir un bénéfice thérapeutique.
MA38949A 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2 MA38949A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361891786P 2013-10-16 2013-10-16
PCT/US2014/060724 WO2015057859A1 (fr) 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2

Publications (1)

Publication Number Publication Date
MA38949A1 true MA38949A1 (fr) 2017-07-31

Family

ID=52828660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38949A MA38949A1 (fr) 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2

Country Status (24)

Country Link
US (3) US10040782B2 (fr)
EP (2) EP4324525A3 (fr)
JP (2) JP6608812B2 (fr)
KR (1) KR102142177B1 (fr)
CN (1) CN105829302B (fr)
AU (2) AU2014337300B2 (fr)
CA (1) CA2925889C (fr)
CL (1) CL2016000866A1 (fr)
DK (1) DK3057962T3 (fr)
EA (1) EA038869B1 (fr)
ES (1) ES2960953T3 (fr)
FI (1) FI3057962T3 (fr)
HU (1) HUE063984T2 (fr)
IL (1) IL244787B (fr)
LT (1) LT3057962T (fr)
MA (1) MA38949A1 (fr)
MX (1) MX2016004703A (fr)
MY (1) MY179802A (fr)
PE (1) PE20161273A1 (fr)
PL (1) PL3057962T3 (fr)
PT (1) PT3057962T (fr)
SG (2) SG11201602269QA (fr)
SI (1) SI3057962T1 (fr)
WO (1) WO2015057859A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2745016T3 (es) 2012-04-13 2020-02-27 Epizyme Inc Bromhidrato de N-((4,6-dimetil-2-oxo-L,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[L,1'-bifenil]-3-carboxamida para su uso en el tratamiento de un trastorno proliferativo celular del sistema hematológico
JP6608812B2 (ja) 2013-10-16 2019-11-20 エピザイム，インコーポレイティド Ｅｚｈ２阻害のための塩酸塩形
CA2931263A1 (fr) 2013-12-06 2015-06-11 Epizyme, Inc. Polytherapie pour le traitement du cancer
SG10201811128RA (en) 2014-06-17 2019-01-30 Epizyme Inc Ezh2 inhibitors for treating lymphoma
AU2015331729A1 (en) 2014-10-16 2017-04-13 Epizyme, Inc. Method for treating cancer
CA2967664A1 (fr) * 2014-11-17 2016-05-26 Epizyme, Inc. Formulations pharmaceutiques comprenant des inhibiteurs de l'histone methyltransferase ezh2 humain
AU2016252546A1 (en) 2015-04-20 2017-11-02 Epizyme, Inc. Combination therapy for treating cancer
US20180311251A1 (en) 2015-06-10 2018-11-01 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
AU2016312514A1 (en) 2015-08-24 2018-03-15 Epizyme, Inc. Method for treating cancer
AU2017211331A1 (en) 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2017218953A1 (fr) 2016-06-17 2017-12-21 Epizyme, Inc. Inhibiteurs d'ezh2 pour traiter le cancer
TW201831181A (zh) 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
CN111093660A (zh) 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
WO2020011607A1 (fr) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition de sous-unités de prc2 permettant de traiter des troubles oculaires
US20220298222A1 (en) 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
CN1118595A (zh) 1993-12-27 1996-03-13 卫材株式会社 氨茴酸衍生物
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6060099A (en) 1998-09-30 2000-04-17 Procter & Gamble Company, The 2-substituted ketoamides
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DK1357111T3 (da) 2000-12-28 2009-11-02 Shionogi & Co 2-pyridonderivater med affinitet for cannabinoid type 2-receptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
ATE447971T1 (de) 2002-02-19 2009-11-15 Shionogi & Co Antipruriginosa
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
EP1765994B1 (fr) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Complexe d'histone methyltransferase reconstitue et methodes associees d'identification de modulateurs
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2006130720A2 (fr) 2005-06-02 2006-12-07 University Of North Carolina At Chapel Hill Purification, caracterisation et reconstitution d'une ubiquitine e3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PL1940821T3 (pl) 2005-10-19 2013-08-30 Gruenenthal Gmbh Nowe ligandy receptora waniloidowego i ich zastosowanie do wytwarzania leków
JP4931930B2 (ja) 2005-10-21 2012-05-16 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャネル阻害剤
EP1941060B1 (fr) 2005-10-28 2012-02-29 The University of North Carolina At Chapel Hill Protéine déméthylase à domaine jmjc
US8163749B2 (en) 2005-12-14 2012-04-24 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US8524467B2 (en) 2006-01-20 2013-09-03 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
US20100016379A1 (en) 2006-05-15 2010-01-21 Irm Llc Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors
EP2040711A2 (fr) 2006-05-18 2009-04-01 Amphora Discovery Corporation Dérivés de 2-oxo-1,2-dihydroquinoline, compositions pharmaceutiques contenant ces composes, et leurs utilisation en tant qu'agents antiprolifératifs
WO2008108825A2 (fr) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Compositions neuroprotectrices et procédés correspondants
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008113006A1 (fr) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Procédés d'utilisation de composés à base de quinolinone dans le traitement des maladies ou des affections associées aux canaux sodiques
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (fr) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions et méthodes pour inhiber la protéine ezh2
EP2215049B1 (fr) 2007-10-31 2019-06-12 Merck Sharp & Dohme Corp. Antagonistes du récepteur p2x3 utilisés dans le traitement de la douleur
WO2009077766A1 (fr) 2007-12-19 2009-06-25 Cancer Research Technology Limited Composés pyrido[2,3-b]pyrazine substitués en position 8 et leur utilisation
WO2009124137A2 (fr) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Procédé de suppression d’une transcription de gène par méthylation d’histone lysine
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
AU2009279616A1 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
WO2011011366A2 (fr) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents pour stimuler l'activité d'enzymes de modification par méthyle et procédés d'utilisation de ceux-ci
US8329149B2 (en) 2009-12-30 2012-12-11 Avon Products, Inc. Topical lightening composition and uses thereof
NZ603454A (en) 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インダゾール
WO2012005805A1 (fr) 2010-05-07 2012-01-12 Glaxosmithkline Llc Aza-indazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
DK2614369T3 (en) 2010-09-10 2016-05-02 Epizyme Inc METHOD FOR DETERMINING THE SUITABILITY OF HUMAN EZH2 INHIBITORS TREATED
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (fr) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
KR20130124959A (ko) 2010-12-03 2013-11-15 에피자임, 인코포레이티드 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CN110420327B (zh) 2012-03-12 2022-05-03 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
SG10201912111TA (en) 2012-04-13 2020-02-27 Epizyme Inc Combination therapy for treating cancer
ES2745016T3 (es) 2012-04-13 2020-02-27 Epizyme Inc Bromhidrato de N-((4,6-dimetil-2-oxo-L,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[L,1'-bifenil]-3-carboxamida para su uso en el tratamiento de un trastorno proliferativo celular del sistema hematológico
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
EP2906538A4 (fr) 2012-10-15 2016-05-11 Epizyme Inc Composés de benzène substitué
CN105142642B (zh) 2012-10-15 2019-10-18 Epizyme股份有限公司 癌症治疗方法
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
WO2014100665A1 (fr) 2012-12-21 2014-06-26 Epizyme, Inc. Composés hétéroaryles bicycliques 1,4-pyridone
EP2970306A4 (fr) 2013-03-15 2016-08-03 Epizyme Inc Composés hétéroaryles bicycliques substitués condensés en 6,5
EP2970281A4 (fr) 2013-03-15 2016-08-03 Epizyme Inc Composés de benzène substitués
WO2015010078A2 (fr) 2013-07-19 2015-01-22 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
JP6608812B2 (ja) 2013-10-16 2019-11-20 エピザイム，インコーポレイティド Ｅｚｈ２阻害のための塩酸塩形

Also Published As

Publication number Publication date
EP3057962B1 (fr) 2023-10-18
US20160237068A1 (en) 2016-08-18
EP3057962A4 (fr) 2017-05-24
SG11201602269QA (en) 2016-04-28
SI3057962T1 (sl) 2024-01-31
EP4324525A3 (fr) 2024-07-17
PL3057962T3 (pl) 2024-01-29
EP3057962A1 (fr) 2016-08-24
CN105829302A (zh) 2016-08-03
AU2014337300A1 (en) 2016-04-14
CN105829302B (zh) 2020-09-08
CA2925889C (fr) 2020-09-29
CA2925889A1 (fr) 2015-04-23
IL244787B (en) 2022-04-01
DK3057962T3 (da) 2023-11-06
IL244787A0 (en) 2016-04-21
JP6608812B2 (ja) 2019-11-20
MX2016004703A (es) 2017-02-28
NZ718201A (en) 2021-09-24
PE20161273A1 (es) 2016-12-18
MY179802A (en) 2020-11-16
JP2016533349A (ja) 2016-10-27
JP2019052181A (ja) 2019-04-04
US20180282312A1 (en) 2018-10-04
US10040782B2 (en) 2018-08-07
US20210017163A1 (en) 2021-01-21
PT3057962T (pt) 2023-11-07
EA201690650A1 (ru) 2016-10-31
CL2016000866A1 (es) 2016-12-23
LT3057962T (lt) 2023-12-11
HUE063984T2 (hu) 2024-02-28
KR102142177B1 (ko) 2020-08-07
AU2014337300B2 (en) 2019-01-03
EA038869B1 (ru) 2021-10-29
WO2015057859A1 (fr) 2015-04-23
ES2960953T3 (es) 2024-03-07
KR20160082993A (ko) 2016-07-11
FI3057962T3 (fi) 2023-11-03
AU2019202246A1 (en) 2019-04-18
US10710987B2 (en) 2020-07-14
EP4324525A2 (fr) 2024-02-21
SG10201901977XA (en) 2019-04-29

Similar Documents

Publication Publication Date Title
MA38949A1 (fr) Forme saline d'hydrochlorure pour inhibition d'ezh2
MA45985A (fr) Inhibiteurs de diacylglycérol acyltransférase 2
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
GEP20237541B (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MA49055B1 (fr) Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf
MA38102A1 (fr) Nouveaux composés utilisés comme inhibiteurs de diacylglycérol acyltransférase
PH12015501109A1 (en) Novel compounds as diacylglycerol acyltransferase inhibitors
MA45990B1 (fr) Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
MA42711A1 (fr) Méthodes de traitement d'états pathologiques associés à une activation du complément dépendant de masp-2
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA38411B1 (fr) Inhibiteurs de cdc7